Table 2 Whole Blood Rapamycin Levels
From: Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model
| Â | 24 hours | 48 hours | ||||
|---|---|---|---|---|---|---|
Treatment Groups | Rapamycin Level (ng/ml) | p value* | Number of Mice | Rapamycin Level (ng/ml) | p value** | Number of Mice |
Treatment Trial (Tumor bearing) | Â | Â | Â | Â | Â | Â |
   0.4% Direct Topical Rapamycin | 6.3 ± 0.6 | 0.02 | 3 | 2.3 ± 0.4 | 0.04 | 3 |
   0.8% Indirect Topical Rapamycin | 11.9 ± 3.2 | 0.92 | 3 | 5.3 ± 0.8 | 0.25 | 3 |
   0.8% Direct Topical Rapamycin | 12.3 ± 1.5 | N/A | 3 | 4.1 ± 0.5 | N/A | 3 |
   0.16 mg Rapamycin IP | 55.9 ± 2.7 | 0.0005 | 2 | 17.4 ± 2.2 | 0.005 | 2 |
Non-Tumor bearing | Â | Â | Â | Â | Â | Â |
   0.4% Topical Rapamycin (1 dose) | 5.9 ± 0.5 | 0.01 | 3 | 1.7 ± 0.9 | 0.07 | 3 |
   0.8% Topical Rapamycin (1 dose) | 13.0 ± 2.5 | 0.81 | 3 | 4.1 ± 2.3 | 0.98 | 3 |
   0.8% Topical Rapamycin + Bandage (1 dose) | 3.4 ± 0.6 | <0.0001 | 8 | 2.6 ± 0.7 | 0.28 | 8 |
   0.8% Topical Rapamycin + Collar (3 doses) | 21.7 ± 3.7 | 0.13 | 6 | Not done | N/A | Not done |